Vesugen (KED)

KED | Vascular Bioregulator Peptide

Weight: 390 Da
Half-life: Not established
Chain: 3 amino acids
3 studies
2020 latest
Moderate Research
Dose 10-20 mg per day (oral capsules) or 10 mg (injectable)
Frequency Daily for 10-20 consecutive days (Khavinson bioregulator cycle)
Cycle 10-20 day cycle
Storage Oral capsules: room temperature; Lyophilized powder/reconstituted: 2-8°C refrigerated

Community Research

Join others researching Vesugen — share findings, ask questions, and learn from real experiences

View Results Aggregated community findings
Discussion Questions & experiences
Submit Your Findings Contribute your research data

Vesugen is a Khavinson bioregulator tripeptide developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology. Composed of three amino acids (lysine, glutamic acid, aspartic acid), it targets the vascular system and protects blood vessels from age-related decline. Research shows it limits atherosclerosis development, decreases endothelial dysfunction, and activates stem cells. Like other short Khavinson peptides, Vesugen penetrates to the nucleus where it influences gene expression.

Mechanism of Action

Vesugen works through epigenetic regulation by interacting with DNA promoter regions, particularly affecting Ki-67 gene expression which controls cell division. It plays a prominent role in regulating sirtuin 1 (SIRT1) protein levels - a key anti-aging protein activated during calorie restriction. Vesugen enhances mesenchymal stem cell proliferation, reduces senescence markers, improves cell differentiation, and may reverse the Senescence-Associated Secretory Phenotype (SASP) implicated in age-related cardiovascular disease.

01 Protects vascular system from aging effects
02 Limits atherosclerosis development
03 Decreases endothelial cell dysfunction
04 Activates SIRT1 anti-aging pathway
05 Enhances stem cell proliferation
06 Reduces cellular senescence markers
07 Reverses SASP phenotype
08 Works synergistically with Cardiogen

Molecular Data

Molecular Weight
390 Da
Chain Length
3 amino acids
Type
Tripeptide bioregulator
Amino Acid Sequence
One-letter: KED
H₂N
K 1
O ‖ C
N
E 2
O ‖ C
N
D 3
COOH
Lys
1

Lysine

Position 1

Glu
2

Glutamic Acid

Position 2

Asp
3

Aspartic Acid

Position 3

N-terminus C-terminus
Hydrophobic
Polar
Positive (+)
Negative (-)
Modified

Research Indications

Vascular Health
Vascular Aging effective

Protects blood vessels from age-related deterioration through gene expression regulation.

Atherosclerosis Prevention moderate

Limits development of atherosclerotic plaques in blood vessels.

Endothelial Function moderate

Decreases endothelial dysfunction that contributes to cardiovascular disease.

Anti-Aging
SIRT1 Activation effective

Regulates sirtuin 1 levels, mimicking some benefits of calorie restriction.

Stem Cell Activation moderate

Enhances mesenchymal stem cell proliferation and reduces senescence.

Cellular Rejuvenation moderate

Reverses senescence-associated secretory phenotype in aging cells.

Dosing Protocols

Available in capsule form for oral administration. Short peptides can be absorbed orally and reach target tissues. Typical protocol involves 10-20 day cycles, often repeated 2-3 times per year.

GoalDoseFrequencyRoute
Standard protocol10-20 mgDaily for 10-20 daysOral capsules
Maintenance10 mg2-3 cycles yearlyOral capsules

Interactions

++
Cardiogen
Complementary cardiovascular bioregulators - Vesugen for vessels, Cardiogen for heart tissue.
synergistic
++
Epitalon
Often combined in comprehensive anti-aging Khavinson protocols.
synergistic
+
Thymalin
Different organ targets; can be used in comprehensive bioregulator protocols.
compatible
+
Pinealon
Part of Khavinson bioregulator family; targets different tissue.
compatible

What to Expect

During cycle
Gene expression modulation and SIRT1 activation begins
Post-cycle
Effects persist due to epigenetic changes
Months
Vascular function improvements
Long-term
Cumulative benefits with periodic cycles

Side Effects & Safety

Common Side Effects

  • Generally well-tolerated
  • Minimal side effects reported

Stop Signs - Discontinue if:

  • Allergic reactions
  • Unusual cardiovascular symptoms

Contraindications

  • Active cardiovascular emergencies (seek medical care)
  • Known hypersensitivity
  • Pregnancy or breastfeeding

Quality Checklist

Good Signs

  • White powder or capsules
  • Clear solution if reconstituted
  • Proper packaging and labeling

Warning Signs

  • Unknown source or purity

Bad Signs

  • Discoloration
  • Unusual odor
  • Damaged packaging

References

  • Khavinson Peptide Bioregulators Research
    Advances in Gerontology (2020)

    Comprehensive review of bioregulator peptides including Vesugen and their epigenetic mechanisms.

  • Short Peptides and Vascular Aging
    Bulletin of Experimental Biology and Medicine (2018)

    Short peptides regulate sirtuin 1 levels and protect vascular tissue from aging.

  • Mesenchymal Stem Cell Activation by Peptide Bioregulators
    Cell Technologies in Biology and Medicine (2019)

    Vesugen enhances MSC proliferation and reduces senescence markers in stem cells.

Related Peptides

Cardiogen synergistic

Complementary cardiovascular bioregulators - Vesugen for vessels, Cardiogen for heart tissue.

Epitalon synergistic

Often combined in comprehensive anti-aging Khavinson protocols.

Thymalin compatible

Different organ targets; can be used in comprehensive bioregulator protocols.

Pinealon compatible

Part of Khavinson bioregulator family; targets different tissue.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.